IL86577A - Antibodies having specific affinity for autocrine motility factor, a kit containing the same, and use thereof to detect the presence of cancer in humans - Google Patents

Antibodies having specific affinity for autocrine motility factor, a kit containing the same, and use thereof to detect the presence of cancer in humans

Info

Publication number
IL86577A
IL86577A IL86577A IL8657788A IL86577A IL 86577 A IL86577 A IL 86577A IL 86577 A IL86577 A IL 86577A IL 8657788 A IL8657788 A IL 8657788A IL 86577 A IL86577 A IL 86577A
Authority
IL
Israel
Prior art keywords
antibodies
humans
cancer
detect
same
Prior art date
Application number
IL86577A
Other languages
English (en)
Other versions
IL86577A0 (en
Original Assignee
Us Commerce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Commerce filed Critical Us Commerce
Publication of IL86577A0 publication Critical patent/IL86577A0/xx
Publication of IL86577A publication Critical patent/IL86577A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL86577A 1987-06-05 1988-05-31 Antibodies having specific affinity for autocrine motility factor, a kit containing the same, and use thereof to detect the presence of cancer in humans IL86577A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5838187A 1987-06-05 1987-06-05

Publications (2)

Publication Number Publication Date
IL86577A0 IL86577A0 (en) 1988-11-15
IL86577A true IL86577A (en) 1993-06-10

Family

ID=22016462

Family Applications (1)

Application Number Title Priority Date Filing Date
IL86577A IL86577A (en) 1987-06-05 1988-05-31 Antibodies having specific affinity for autocrine motility factor, a kit containing the same, and use thereof to detect the presence of cancer in humans

Country Status (6)

Country Link
EP (1) EP0362278A4 (fr)
JP (1) JP2851288B2 (fr)
AU (1) AU614755B2 (fr)
CA (1) CA1310902C (fr)
IL (1) IL86577A (fr)
WO (1) WO1988009797A1 (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE455946B (sv) * 1986-10-20 1988-08-22 Trion Forskning & Utveckling Nya pertussistoxin-polypeptider och antigener samt testsatser, vacciner och intradermala hudtestkompositioner
US5449753A (en) * 1992-01-17 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services Autotaxin: motility stimulating protein useful in cancer diagnosis
US5382521A (en) * 1992-07-14 1995-01-17 Michigan Cancer Foundation Method of determining metastatic potential of bladder tumor cells
CA2238257A1 (fr) * 1998-05-22 1999-11-22 Universite De Montreal Endocytose d'un recepteur de facteur autocrine de mobilite (amf-r) et utilisations dans le traitement des cancers
DE19847107A1 (de) * 1998-10-13 2000-04-20 Herbert Ruebben Verwendung von Pertussistoxin zur Behandlung von Tumorerkrankungen
KR100629028B1 (ko) 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
WO2001074897A2 (fr) * 2000-04-03 2001-10-11 Curagen Corporation Proteines et acides nucleiques codant pour lesdites proteines
EP2269638A3 (fr) 2004-05-28 2012-06-13 GlaxoSmithKline Biologicals S.A. Compositions de vaccin comprenant des virosomes et un adjuvant à base de saponine
AR054020A1 (es) 2005-03-23 2007-05-30 Glaxosmithkline Biolog Sa Nuevo uso
GB0519871D0 (en) 2005-09-30 2005-11-09 Secr Defence Immunogenic agents
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
KR101515078B1 (ko) 2005-12-22 2015-04-24 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
EP2476433A1 (fr) 2006-03-30 2012-07-18 GlaxoSmithKline Biologicals S.A. Composition immunogène
PT2422810E (pt) 2006-07-17 2014-12-03 Glaxosmithkline Biolog Sa Vacina da gripe
US9364525B2 (en) 2006-07-18 2016-06-14 Glaxosmithkline Biologicals Sa Vaccines for malaria
US8323664B2 (en) 2006-07-25 2012-12-04 The Secretary Of State For Defence Live vaccine strains of Francisella
EA015817B1 (ru) 2006-10-12 2011-12-30 Глаксосмитклайн Байолоджикалс С.А. Иммуногенная композиция, содержащая адъювант в виде эмульсии "масло в воде"
EP2433648A3 (fr) 2006-10-12 2012-04-04 GlaxoSmithKline Biologicals S.A. Vaccin comprenant une émulsion adjuvante huile en l'eau
PE20090146A1 (es) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
CA2690708A1 (fr) 2007-06-26 2008-12-31 Glaxosmithkline Biologicals S.A. Vaccin
WO2009117035A1 (fr) 2007-12-19 2009-09-24 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Formes solubles de la glycoprotéine f des virus hendra et nipah et leurs utilisations
ES2553113T3 (es) 2008-04-16 2015-12-04 Glaxosmithkline Biologicals S.A. Vacuna
GB0900455D0 (en) 2009-01-13 2009-02-11 Secr Defence Vaccine
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
MX2012011189A (es) 2010-03-26 2013-02-07 Glaxosmithkline Biolog Sa Vacuna contra el virus e inmunodeficiencia humana.
GB201009273D0 (en) 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
EP2707025B8 (fr) 2011-05-13 2017-08-23 Zoetis Services LLC Compositions immunogènes contre la glycoprotéine g des virus hendra et nipah
CN103533953A (zh) 2011-05-17 2014-01-22 葛兰素史密丝克莱恩生物有限公司 针对肺炎链球菌的疫苗
GB201120000D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
GB201119999D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
WO2014086787A1 (fr) 2012-12-05 2014-06-12 Glaxosmithkline Biologicals S.A. Composition immunogène
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
MX2016007870A (es) 2013-12-16 2016-10-07 Zoetis Services Llc Composiciones inmunogenas de glucoproteina g de los virus hendra y nipah.
BE1022949B1 (fr) 2014-06-25 2016-10-21 Glaxosmithkline Biologicals S.A. Composition immunogene
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
CN110621339A (zh) 2017-04-28 2019-12-27 葛兰素史密丝克莱恩生物有限公司 疫苗接种
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600653B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel methods
EP3581201A1 (fr) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 polypeptides et leurs utilisations
WO2019245266A1 (fr) * 2018-06-20 2019-12-26 박희성 Composition anticancéreuse contenant en tant que principe actif une cytokine issue de cancers, l'amf
CN112566654A (zh) 2018-07-31 2021-03-26 葛兰素史密丝克莱恩生物有限公司 抗原纯化方法
WO2020055503A1 (fr) 2018-09-14 2020-03-19 Massachusetts Institute Of Technology Adjuvant vaccinal à base de nanoparticules, et méthodes d'utilisation associées
EP3886901A1 (fr) 2018-11-29 2021-10-06 GlaxoSmithKline Biologicals S.A. Procédés de fabrication d'un adjuvant
CN114126419A (zh) 2019-03-19 2022-03-01 Uab研究基金会 基于皂苷的疫苗佐剂
EP3777884A1 (fr) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Composition immunogène
WO2021048081A1 (fr) 2019-09-09 2021-03-18 Glaxosmithkline Biologicals Sa Compositions immunothérapeutiques
US12533418B2 (en) 2019-11-22 2026-01-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
WO2021122551A1 (fr) 2019-12-19 2021-06-24 Glaxosmithkline Biologicals Sa Antigènes de s. aureus et compositions associées
EP4146378A1 (fr) 2020-05-05 2023-03-15 GlaxoSmithKline Biologicals S.A. Dispositif de mélange microfluidique et procédés d'utilisation
WO2022029024A1 (fr) 2020-08-03 2022-02-10 Glaxosmithkline Biologicals Sa PROTÉINE FUSOBACTERIUM ADHÉSINE A (FadA) DE FUSOBACTERIUM NUCLEATUM TRONQUÉE ET COMPOSITIONS IMMUNOGÈNES À BASE DE CELLE-CI
TW202214294A (zh) 2020-09-30 2022-04-16 美商碩騰服務公司 具有ｈｙａＣ及ｎａｎＰ缺失之新穎多殺性巴斯德氏菌株及疫苗
JP2023553854A (ja) 2020-12-02 2023-12-26 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ドナー鎖補完性ｆｉｍｈ
WO2023020992A1 (fr) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Nouveaux procédés
WO2023020994A1 (fr) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Nouveaux procédés
WO2023020993A1 (fr) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Nouveaux procédés
WO2023114570A1 (fr) 2021-12-19 2023-06-22 Massachusetts Institute Of Technology Compositions et méthodes pour obtenir des réponses durables des centres germinatifs à une sensibilisation active
JP2025509460A (ja) 2022-03-14 2025-04-11 ファイザー・インク アジュバントを生産するための方法
TWI909678B (zh) 2023-09-13 2025-12-21 美商輝瑞股份有限公司 產製佐劑之方法

Also Published As

Publication number Publication date
IL86577A0 (en) 1988-11-15
AU614755B2 (en) 1991-09-12
CA1310902C (fr) 1992-12-01
EP0362278A1 (fr) 1990-04-11
EP0362278A4 (fr) 1990-05-14
JP2851288B2 (ja) 1999-01-27
WO1988009797A1 (fr) 1988-12-15
JPH04502143A (ja) 1992-04-16
AU1803488A (en) 1989-01-04

Similar Documents

Publication Publication Date Title
IL86577A (en) Antibodies having specific affinity for autocrine motility factor, a kit containing the same, and use thereof to detect the presence of cancer in humans
EP0323055A3 (en) Composition chromatographic article
GB8905669D0 (en) Modified antibodies
IL78993A0 (en) Antibodies and kit for use in radiotherapy and radioimmunoassay utilizing the same
IL84160A0 (en) Method and kit for immune complex assay
GB8909702D0 (en) Improvements relating to biosensors
EP0285511A3 (en) Monoclonal antibodies and their uses
IL87730A0 (en) Peptides and antibodies
GR910300146T1 (en) Grenade for multi-purpose use
EP0348494A4 (en) Dioxetanes for use in assays
GB8716818D0 (en) Pen
GB8902771D0 (en) Improvements in or relating to affinity chromatography
GB8910912D0 (en) Improvements in or relating to ring binder mechanisms
GB8726230D0 (en) Antibodies
GB9014409D0 (en) Compact pen
GB8920375D0 (en) Improvements in or relating to piston rings
GB8915823D0 (en) Pneumatic small limina bypass
ZA891760B (en) Thermo-couples
GB8824291D0 (en) Novel use
EP0381763A4 (en) Antibody modified with toxin
EP0423333A4 (en) Anti-endoserine antibody
HU896325D0 (en) Peptides binding to antibody
GB8909129D0 (en) Multi-purpose bookrest
GB8907576D0 (en) Improvements relating to biosensors
GB8805240D0 (en) Improvements relating to antigen

Legal Events

Date Code Title Description
KB Patent renewed
RH Patent void
KB Patent renewed
KB Patent renewed
EXP Patent expired